Difference between revisions of "PRAME"

From Libre Pathology
Jump to navigation Jump to search
(Created page with "'''PRAME''' is an immunostain that is typically positive in malignant melanoma.<ref>{{cite journal |authors=Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ |t...")
 
Line 1: Line 1:
'''PRAME''' is an [[immunostain]] that is typically positive in [[malignant melanoma]].<ref>{{cite journal |authors=Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ |title=PRAME Expression in Melanocytic Tumors |journal=Am J Surg Pathol |volume=42 |issue=11 |pages=1456–1465 |date=November 2018 |pmid=30045064 |pmc=6631376 |doi=10.1097/PAS.0000000000001134 |url=}}</ref>
'''PRAME''' is an [[immunostain]] that is typically positive in [[malignant melanoma]].<ref name=pmid30045064>{{cite journal |authors=Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ |title=PRAME Expression in Melanocytic Tumors |journal=Am J Surg Pathol |volume=42 |issue=11 |pages=1456–1465 |date=November 2018 |pmid=30045064 |pmc=6631376 |doi=10.1097/PAS.0000000000001134 |url=}}</ref>
 
==General==
 
==Positive staining==
*80-85% of primary melanomas.<ref name=pmid30045064/>
*85-90% of metastatic melanomas.<ref name=pmid30045064/>


==See also==
==See also==

Revision as of 21:18, 4 March 2025

PRAME is an immunostain that is typically positive in malignant melanoma.[1]

General

Positive staining

  • 80-85% of primary melanomas.[1]
  • 85-90% of metastatic melanomas.[1]

See also

References

  1. Jump up to: 1.0 1.1 1.2 Lezcano C, Jungbluth AA, Nehal KS, Hollmann TJ, Busam KJ (November 2018). "PRAME Expression in Melanocytic Tumors". Am J Surg Pathol 42 (11): 1456–1465. doi:10.1097/PAS.0000000000001134. PMC 6631376. PMID 30045064. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631376/.